Literature DB >> 25908719

Psoriasis Phenotype in Inflammatory Bowel Disease: A Case-Control Prospective Study.

Elisabetta Lolli1, Rosita Saraceno2, Emma Calabrese1, Marta Ascolani1, Patrizio Scarozza1, Andrea Chiricozzi2, Sara Onali1, Carmelina Petruzziello1, Sergio Chimenti2, Francesco Pallone1, Livia Biancone3.   

Abstract

BACKGROUND AND AIMS: Whether inflammatory bowel disease [IBD] is associated with specific psoriasis phenotypes is undefined. In a case-control prospective study, we aimed to assess the severity and phenotype of psoriasis in IBD vs matched non-IBD controls with psoriasis [non-IBD].
METHODS: From 2011 to 2013, dermatological assessment was performed in all IBD patients showing lesions requiring characterisation. In patients with psoriasis, assessment included: presence, characteristics, and severity. Each IBD patient with psoriasis was matched [gender, ethnicity, age ± 5 years] with one non-IBD patient with psoriasis. STATISTICAL ANALYSIS: data were expressed as median [range], chi-square, Student's t test.
RESULTS: Dermatological assessment was performed in 251 IBD patients [115 females, age 47 [16-85]; IBD duration 9 years [1-46]]: 158 Crohn's disease [CD] [63%], 93 ulcerative colitis [UC] [37%]. Psoriasis was detected in 62 [25%] IBD patients: 36 [58%] CD, 26 UC [42%; p = 0.44]. Clinical characteristics were comparable between IBD patients with or without psoriasis: age 50 [23-72] vs 47 [16-85]; IBD duration 9.5 [1-46] vs 9 [1-41]; p = non-significant]. The non-IBD group included 62 patients with psoriasis: 35 male; age 47 [18-75]. Mild psoriasis was more frequent in IBD vs non-IBD [87% vs 53%; p < 0.0001], whereas moderate and severe psoriasis were more frequent in non-IBD vs IBD [37% vs 13%, p = 0.004; 10% vs 0%; p = 0.036]. Plaque-type psoriasis was the most common phenotype in both IBD and non-IBD [p < 0.0001 vs others phenotypes].The frequency of plaque-type, nail psoriasis and psoriatic arthritis was lower in IBD vs non-IBD [p = 0.008; p < 0.0001; p = 0.006]. Psoriasis occurred after anti-tumour necrosis factor [TNF]α treatment in six CD patients [7%].
CONCLUSIONS: Severity and phenotypes of psoriasis may differ between patients with IBD and their matched non-IBD controls.
Copyright © 2015 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Crohn’s disease; phenotype; psoriasis; severity; ulcerative colitis

Mesh:

Year:  2015        PMID: 25908719     DOI: 10.1093/ecco-jcc/jjv068

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  5 in total

1.  Antitumor necrosis factor treatment in patients with inflammatory bowel disease does not promote psoriasis development: A meta-analysis.

Authors:  Yu Kyung Jun; Joo Young Park; Seong-Joon Koh; Hyunsun Park; Hyoun Woo Kang; Jong Pil Im; Joo Sung Kim
Journal:  Medicine (Baltimore)       Date:  2022-07-08       Impact factor: 1.817

2.  Debut of Psoriasis is usually before Debut of Concomitant Inflammatory Bowel Disease: A Population-based Retrospective Study.

Authors:  Klas Agerberg; Anders Rönnblom
Journal:  Acta Derm Venereol       Date:  2022-05-16       Impact factor: 3.875

3.  Impact of immune-mediated diseases in inflammatory bowel disease and implications in therapeutic approach.

Authors:  M J García; M Pascual; C Del Pozo; A Díaz-González; B Castro; L Rasines; J Crespo; M Rivero
Journal:  Sci Rep       Date:  2020-07-01       Impact factor: 4.379

Review 4.  Inflammatory bowel disease and immune-mediated inflammatory diseases: looking at the less frequent associations.

Authors:  Cristina Bezzio; Cristina Della Corte; Marta Vernero; Imma Di Luna; Gianpiero Manes; Simone Saibeni
Journal:  Therap Adv Gastroenterol       Date:  2022-07-28       Impact factor: 4.802

Review 5.  Psoriasis and inflammatory bowel disease: links and risks.

Authors:  Christoforos Vlachos; Georgios Gaitanis; Konstantinos H Katsanos; Dimitrios K Christodoulou; Epameinondas Tsianos; Ioannis D Bassukas
Journal:  Psoriasis (Auckl)       Date:  2016-07-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.